A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial
Abstract Background As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim o...
Main Authors: | Hideo Saka, Chiyoe Kitagawa, Yukito Ichinose, Mitsuhiro Takenoyama, Hidenori Ibata, Tatsuo Kato, Koji Takami, Motohiro Yamashita, Tadashi Maeda, Sadanori Takeo, Hitoshi Ueda, Kan Okabayashi, Seiji Nagashima, Tadayuki Oka, Hidenori Kouso, Seiichi Fukuyama, Kentaro Yoshimoto, Mototsugu Shimokawa, Akiko M. Saito, Suminobu Ito |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-017-2103-4 |
Similar Items
-
Synthesis of a 2ꞌꞌ-Deoxy-β-GalCer
by: Meena S. Thakur, et al.
Published: (2014-07-01) -
Interaction between Bacteria and the Immune System for Cancer Immunotherapy: The α-GalCer Alliance
by: Arsenij Ustjanzew, et al.
Published: (2022-05-01) -
α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials
by: Yingting Zhang, et al.
Published: (2019-06-01) -
Alpha-galactosylceramide (αGalCer) enhances vaccine-induced protection in a model of ricin intoxication
by: Jennifer L. Yates, et al.
Published: (2018-08-01) -
Tumor-Localized Administration of α-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors
by: Yan-Ruide Li, et al.
Published: (2022-07-01)